Study of prognostic significance of bundle branch blocks in acute coronary syndrome

2019 ◽  
Vol 12 (3) ◽  
pp. 96-99
Author(s):  
P T Gajbhare ◽  
◽  
Abhishek Agarwal ◽  
Milind Karade ◽  
◽  
...  
2014 ◽  
Vol 13 (2) ◽  
pp. 78-88 ◽  
Author(s):  
Nasreen Chowdhury ◽  
Md. Aminul Haque Khan ◽  
Md Mozammel Hoque

Acute Coronary syndrome (ACS) is the most common cause of admission to the coronary care unit with highest risk of death and adverse outcomes. ACS accounts for 60–70% of all admissions in the hospital. Patients with ACS encompass a heterogeneous group that varies widely regarding severity of the underlying coronary artery disease, prognosis and response to treatment. Patients with the highest risk of subsequent events usually have the largest benefit of an intensified pharmacological treatment and early mechanical intervention. The prognosis for low-risk patients, on the other hand, is often difficult to improve further and these patients usually benefit more from a conservative management with a lower risk of side effects. Therefore, risk stratification is essential and should be initiated early and updated continuously throughout the hospital stay. Early risk stratification is usually performed by the use of clinical background factors, clinical presentation, electrocardiography and biochemical markers of myocardial damage. Levels of natriuretic peptides have been shown to reflect cardiac performance. The aim of this study was to review elaborately on B type Natriuretic Peptide (BNP) and its prognostic value in patient with ACS. This review focuses on the emerging role of these peptides in the early risk stratification of ACS patients. Elevation of BNP levels in acute MI and UA is predictive of a greater risk of death, post infarction heart failure, or  reinfarction. Post infarction studies demonstrate that elevated plasma BNP levels are associated with larger infarct size, increased probability of ventricular remodeling, lower ejection fraction, higher risk of heart failure, and increased mortality. This cardiac marker is a potent predictor of mortality in patients with all forms ACS. BNP measurements serve as an index of severity of the ischemic injury, as well as the degree of impairment in left ventricular function.DOI: http://dx.doi.org/10.3329/cmoshmcj.v13i2.21079


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Diana Ernst ◽  
Johan Westerbergh ◽  
Georgios Sogkas ◽  
Alexandra Jablonka ◽  
Gerrit Ahrenstorf ◽  
...  

Abstract Although several risk factors exist for acute coronary syndrome (ACS) no biomarkers for survival or risk of re-infarction have been validated. Previously, reduced serum concentrations of anti-ß1AR Ab have been implicated in poorer ACS outcomes. This study further evaluates the prognostic implications of anti-ß1AR-Ab levels at the time of ACS onset. Serum anti-ß1AR Ab concentrations were measured in randomly selected patients from within the PLATO cohort. Stratification was performed according to ACS event: ST-elevation myocardial infarct (STEMI) vs. non-ST elevation myocardial infarct (NSTEMI). Antibody concentrations at ACS presentation were compared to 12-month all-cause and cardiovascular mortality, as well as 12-month re-infarction. Sub-analysis, stratifying for age and the correlation between antibody concentration and conventional cardiac risk-factors was subsequently performed. Serum anti-ß1AR Ab concentrations were measured in 400/799 (50%) STEMI patients and 399 NSTEMI patients. Increasing anti-ß1AR Ab concentrations were associated with STEMI (p = 0.001). Across all ACS patients, no associations between anti-ß1AR Ab concentration and either all-cause cardiovascular death or myocardial re-infarction (p = 0.14) were evident. However among STEMI patients ≤60 years with anti-ß1AR Ab concentration <median higher rates of re-infarction were observed, compared to those with anti-ß1AR Ab concentrations > median (14/198 (7.1%) vs. 2/190 (1.1%)); p = 0.01). Similarly, the same sub-group demonstrated greater risk of cardiovascular death in year 1, including re-infarction and stroke (22/198 (11.1%) vs. 10/190 (5.3%); p = 0.017). ACS Patients ≤60 years, exhibiting lower concentrations of ß1AR Ab carry a greater risk for early re-infarction and cardiovascular death. Large, prospective studies quantitatively assessing the prognostic relevance of Anti-ß1AR Ab levels should be considered.


Circulation ◽  
2001 ◽  
Vol 103 (5) ◽  
pp. 643-650 ◽  
Author(s):  
John W. Eikelboom ◽  
Sonia S. Anand ◽  
Shamir R. Mehta ◽  
Jeffrey I. Weitz ◽  
Cheelong Yi ◽  
...  

Circulation ◽  
2009 ◽  
Vol 119 (18) ◽  
pp. 2454-2462 ◽  
Author(s):  
Tracy Y. Wang ◽  
Fang-Shu Ou ◽  
Matthew T. Roe ◽  
Robert A. Harrington ◽  
E. Magnus Ohman ◽  
...  

2004 ◽  
Vol 94 (12) ◽  
pp. 1543-1547 ◽  
Author(s):  
Raphaëlle Dumaine ◽  
Jean-Philippe Collet ◽  
Marie-Laure Tanguy ◽  
Nicolas Mansencal ◽  
Jean-Luc Dubois-Randé ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document